{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T02:01:20Z","timestamp":1793757680559,"version":"4.6.1"},"reference-count":20,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,8]],"date-time":"2023-08-08T00:00:00Z","timestamp":1691452800000},"content-version":"am","delay-in-days":372,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Rheumatic Disease Clinics of North America"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.rdc.2022.03.005","type":"journal-article","created":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T01:16:33Z","timestamp":1656983793000},"page":"679-689","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":129,"title":["Treatment Guidelines in Rheumatoid Arthritis"],"prefix":"10.1016","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3485-0006","authenticated-orcid":false,"given":"Jasvinder A.","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.rdc.2022.03.005_bib1","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1002\/art.41752","article-title":"American College of Rheumatology guideline for the treatment of rheumatoid arthritis","volume":"73","author":"Fraenkel","year":"2021","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"10.1016\/j.rdc.2022.03.005_bib2","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs","volume":"79","author":"Smolen","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.rdc.2022.03.005_bib4","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.3899\/jrheum.110207","article-title":"Canadian Rheumatology Association recommendations for pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs","volume":"39","author":"Bykerk","year":"2012","journal-title":"J\u00a0Rheumatol"},{"issue":"4","key":"10.1016\/j.rdc.2022.03.005_bib5","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1136\/ard.2009.123919","article-title":"Treating rheumatoid arthritis to target: recommendations of an international task force","volume":"69","author":"Smolen","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.rdc.2022.03.005_bib6","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1002\/acr.24130","article-title":"American College of Rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases","volume":"72","author":"Sammaritano","year":"2020","journal-title":"Arthritis Care Res"},{"issue":"8","key":"10.1016\/j.rdc.2022.03.005_bib7","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1002\/art.40149","article-title":"American College of Rheumatology\/American Association of Hip and Knee Surgeons guideline for the perioperative management of antirheumatic medication in patients with rheumatic diseases undergoing elective total hip or total knee arthroplasty","volume":"69","author":"Goodman","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"12","key":"10.1016\/j.rdc.2022.03.005_bib8","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1093\/rheumatology\/kex389","article-title":"BSR and BHPR guideline for the prescription and monitoring of non-biologic disease-modifying anti-rheumatic drugs","volume":"56","author":"Ledingham","year":"2017","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"10.1016\/j.rdc.2022.03.005_bib9","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1007\/s40674-020-00163-w","article-title":"Treatment guidelines in rheumatoid arthritis: optimizing the best of both worlds","volume":"6","author":"Jagpal","year":"2020","journal-title":"Curr Treat Options Rheumatol"},{"issue":"1","key":"10.1016\/j.rdc.2022.03.005_bib10","doi-asserted-by":"crossref","DOI":"10.1186\/s41927-019-0090-7","article-title":"A\u00a0systematic review of guidelines for managing rheumatoid arthritis","volume":"3","author":"Mian","year":"2019","journal-title":"BMC Rheumatol"},{"issue":"1","key":"10.1016\/j.rdc.2022.03.005_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.39480","article-title":"American College of Rheumatology guideline for the treatment of rheumatoid arthritis","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"10.1016\/j.rdc.2022.03.005_bib12","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/acr.21641","article-title":"2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Review","volume":"64","author":"Singh","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"6","key":"10.1016\/j.rdc.2022.03.005_bib13","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1002\/art.23721","article-title":"American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis","volume":"59","author":"Saag","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.rdc.2022.03.005_bib14","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update","volume":"76","author":"Smolen","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.rdc.2022.03.005_bib15","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1136\/annrheumdis-2013-204573","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update","volume":"73","author":"Smolen","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.rdc.2022.03.005_bib16","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1136\/ard.2009.126532","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs","volume":"69","author":"Smolen","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.rdc.2022.03.005_bib17","first-page":"201","article-title":"Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis","volume":"79","author":"Kerschbaumer","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.rdc.2022.03.005_bib25","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1093\/rheumatology\/kel216a","article-title":"BSR\/BHPR guideline for disease-modifying anti-rheumatic drug (DMARD) therapy in consultation with the British Association of Dermatologists","volume":"47","author":"Chakravarty","year":"2008","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.rdc.2022.03.005_bib26","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1093\/rheumatology\/key298","article-title":"The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis","volume":"58","author":"Holroyd","year":"2019","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"10.1016\/j.rdc.2022.03.005_bib28","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.rdc.2022.03.005_bib29","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1056\/NEJMe2117663","article-title":"Risks and benefits of Janus kinase inhibitors in rheumatoid arthritis: past, present, and future","volume":"386","author":"Singh","year":"2022","journal-title":"N\u00a0Engl J Med"}],"container-title":["Rheumatic Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X22000308?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X22000308?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T11:29:08Z","timestamp":1760182148000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889857X22000308"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["S0889857X22000308"],"URL":"https:\/\/doi.org\/10.1016\/j.rdc.2022.03.005","relation":{},"ISSN":["0889-857X"],"issn-type":[{"value":"0889-857X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment Guidelines in Rheumatoid Arthritis","name":"articletitle","label":"Article Title"},{"value":"Rheumatic Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rdc.2022.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}